Literature DB >> 15897673

Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man.

Torsten Passie1, Matthias Karst, Birgitt Wiese, Hinderk M Emrich, Udo Schneider.   

Abstract

This is the first neuropsychological study using the S-enantiomer of the noncompetitive N-methyl-D-aspartate antagonist ketamine. In 2 randomized placebo-controlled trials we studied effects of two different doses of (S)-ketamine (low dose/high dose) on neuropsychological functions and psychopathology in 12 healthy male volunteers. Impairment was measured via standardized neuropsychological tests. Results indicate that both subanaesthetic doses produce only nonsignificant impairment in most of the tasks. Tasks involving divided and sustained attention as well as scores for objective and subjective psychopathology show significant impairment in a dose-dependent manner. Implications of these findings for the neuropsychology of attention and schizophrenia are discussed. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897673     DOI: 10.1159/000085724

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  10 in total

Review 1.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

Review 2.  Translational research in central nervous system drug discovery.

Authors:  Orest Hurko; John L Ryan
Journal:  NeuroRx       Date:  2005-10

Review 3.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-10

4.  Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers.

Authors:  Erik Olofsen; Ingeborg Noppers; Marieke Niesters; Evan Kharasch; Leon Aarts; Elise Sarton; Albert Dahan
Journal:  Anesthesiology       Date:  2012-08       Impact factor: 7.892

5.  Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggest Dentate Gyrus Pathology Linked to NMDA Receptor Hypofunction.

Authors:  Nina Vanessa Kraguljac; Matthew Carle; Michael A Frölich; Steve Tran; Michael A Yassa; David Matthew White; Abhishek Reddy; Adrienne Carol Lahti
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2021-10-12

6.  Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia.

Authors:  Gary Gilmour; Elsa Y Pioli; Sophie L Dix; Janice W Smith; Michael W Conway; Wendy T Jones; Sally Loomis; Rebecca Mason; Shahram Shahabi; Mark D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2009-05-07       Impact factor: 4.530

7.  The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia.

Authors:  Garry D Honey; Chris O'loughlin; Danielle C Turner; Edith Pomarol-Clotet; Philip R Corlett; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2006-02       Impact factor: 7.853

8.  The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.

Authors:  Aurora J A E van de Loo; Adriana C Bervoets; Loes Mooren; Noor H Bouwmeester; Johan Garssen; Rob Zuiker; Guido van Amerongen; Joop van Gerven; Jaskaran Singh; Peter Van der Ark; Maggie Fedgchin; Randall Morrison; Ewa Wajs; Joris C Verster
Journal:  Psychopharmacology (Berl)       Date:  2017-07-28       Impact factor: 4.530

9.  RETRACTED: Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggests Dentate Gyrus Pathology Linked to N-Methyl-D-Aspartate Receptor Hypofunction.

Authors:  Nina Vanessa Kraguljac; Matthew Carle; Michael A Frölich; Steve Tran; Michael A Yassa; David Matthew White; Abhishek Reddy; Adrienne Carol Lahti
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-02-28

10.  NMDA receptor antagonist ketamine impairs feature integration in visual perception.

Authors:  Julia D I Meuwese; Anouk M van Loon; H Steven Scholte; Philipp B Lirk; Nienke C C Vulink; Markus W Hollmann; Victor A F Lamme
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.